BioNxt Solutions Reports Significant Preclinical Advance for MS Treatment

BioNxt Solutions Inc. has announced a key preclinical milestone for its experimental multiple sclerosis therapy. The Canadian biotechnology firm’s innovative oral film formulation demonstrated a substantial improvement in drug delivery compared to standard tablets in a recent study, paving the way for upcoming human clinical trials.

The company’s strategy centers on reformulating established or advanced drug compounds using its proprietary delivery platform, rather than discovering new molecules. This approach has the potential to streamline regulatory pathways. The initial target is the global multiple sclerosis market, where comparable cladribine-based therapies like Mavenclad generate annual revenues exceeding $1.2 billion, a segment experiencing consistent double-digit growth.

BioNxt’s needle-free, swallow-free sublingual Read more...